Ioversol
Optiray (ioversol) is a small molecule pharmaceutical. Ioversol was first approved as Optiray 320 on 1988-12-30.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Optiray (discontinued: Optiray)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ioversol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OPTIRAY 320 | Liebel-Flarsheim | N-019710 RX | 1988-12-30 | 1 products, RLD, RS |
| OPTIRAY 300 | Liebel-Flarsheim | N-019710 RX | 1992-01-22 | 1 products, RLD, RS |
| OPTIRAY 350 | Liebel-Flarsheim | N-019710 RX | 1992-01-22 | 1 products, RLD, RS |
| OPTIRAY 320 | Liebel-Flarsheim | N-020923 RX | 1998-05-29 | 1 products, RLD, RS |
| OPTIRAY 350 | Liebel-Flarsheim | N-020923 RX | 1998-05-28 | 1 products, RLD, RS |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| optiary optiray optiray | New Drug Application | 2009-01-06 |
| optiray | New Drug Application | 2025-07-29 |
| optiray 160 optiray 240 optiray 300 optiray 320 optiray 350 | 2008-06-23 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | — | N19 | — | — | — | 2 | — | 2 |
| Hypothyroidism | D007037 | EFO_0004705 | E03.9 | — | — | — | 1 | — | 1 |
| Cytokinesis | D048749 | — | — | — | — | — | 1 | — | 1 |
| Coronary disease | D003327 | — | — | — | — | — | 1 | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 2 | 2 | 1 | — | — | 4 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | 1 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Graft vs host disease | D006086 | — | D89.81 | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Cerebral hemorrhage | D002543 | — | — | — | — | — | — | 1 | 1 |
| Intraoperative complications | D007431 | — | — | — | — | — | — | 1 | 1 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 1 | 1 |
| Gallstones | D042882 | EFO_0004210 | — | — | — | — | — | 1 | 1 |
| Laparoscopic cholecystectomy | D017081 | — | — | — | — | — | — | 1 | 1 |
| Cholelithiasis | D002769 | EFO_0004799 | K80 | — | — | — | — | 1 | 1 |
| Cholecystolithiasis | D041761 | EFO_1000864 | — | — | — | — | — | 1 | 1 |
| Biliary tract diseases | D001660 | EFO_0009534 | K83.9 | — | — | — | — | 1 | 1 |
| Choledocholithiasis | D042883 | EFO_1000865 | — | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ioversol |
| INN | ioversol |
| Description | Ioversol is an amidobenzoic acid. |
| Classification | Small molecule |
| Drug class | iodine-containing contrast media |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I |
Identifiers
| PDB | — |
| CAS-ID | 87771-40-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200614 |
| ChEBI ID | — |
| PubChem CID | 3741 |
| DrugBank | DB09134 |
| UNII ID | N3RIB7X24K (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,564 documents
View more details
Safety
Black-box Warning
Black-box warning for: Optiary optiray optiray, Optiray, Optiray 160 optiray 240 optiray 300 optiray 320 optiray 350
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,365 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use